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Background
Type 1 regulatory T (Tr1) cells are an inducible subset of
regulatory T cells that play a pivotal role in promoting and
maintaining tolerance. The main mechanisms by which
Tr1 cells control immune responses are the secretion of
high levels of IL-10, and the killing of myeloid myeloid
cells through the release of Granzyme B. To date a defined
cell surface signature has not been identified for Tr1 cells
and their characterization has thus relied on their unique
cytokine production profile. Tr1 cells secrete high levels of
IL-10 and minimal amounts of IL-4 and IL-17, which dis-
tinguish them from Th2 and Th17 [1]. Furthermore, Tr1
cells secrete low levels of IL-2, and depending on the local
cytokine milieu can produce variable levels of IFN-g. Simi-
lar to other T cell subsets, Tr1 cells can transiently express
FOXP3 upon activation; however, in Tr1 cells FOXP3
expression is not constitutive and never reaches the high
levels characteristic of CD25+Foxp3+ regulatory T cells.
During the last decade, regulatory T cell-based therapies
have become an attractive therapeutic option for indu-
cing/restoring tolerance. Several protocols to generate Tr1
cells in vitro or to isolate Tr1 cell clones have been devel-
oped. We established a reproducible method to generate
allo-specific Tr1 cells in vitro using recombinant IL-10 or
IL-10-derived from tolerogenic dendritic cells (DC).
Results
Tr1 cells are induced in vitro using a new subset of human
tolerogenic dendritic cells (DC), termed DC-10, which are
present in vivo and inducible in vitro from monocytes in
the presence of IL-10 [2]. Resulting T cells are anergic,
secrete significant levels of IL-10, and suppress T cell
responses in vitro in an IL-10-dependent manner. Adop-
tive transfer of ex vivo induced alloantigen-specific Tr1
cells has proven to be feasible and safe, and can be applied
in allogeneic hematopoietic stem cell transplantation. An
alternative strategy for the induction of high numbers of
human Tr1 cells is lentiviral-mediated gene transfer of
human IL-10. Stable ectopic expression of IL-10 can effi-
ciently generate homogeneous populations of Tr1-like
cells [3]. These cells display potent suppressive functions
both in vitro and in vivo in xenogeneic graft versus host
disease model, while preserving the graft versus leukemia
effects.
Conclusions
Tr1 cells can be induced in vitro for Tr1-based cell ther-
apy aimed at restoring peripheral tolerance in immune-
mediated diseases.
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